HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.

Abstract
Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23, a protein expressed on virtually all chronic lymphocytic leukemia (CLL) cells. We examined the ability of lumiliximab to mediate apoptosis, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity against primary CLL cells and CD23-expressing B-cell lines. Our data suggest that lumiliximab kills CLL cells and CD23-expressing B cells predominantly by apoptosis, which occurs through the intrinsic pathway. Lumiliximab-induced apoptosis was accompanied by the down-regulation of antiapoptotic proteins Bcl-2, Bcl-X(L), and XIAP, activation of Bax, and release of cytochrome c from the mitochondria. We also found that the addition of lumiliximab to rituximab or fludarabine results in synergistic cytotoxicity of primary CLL cells and CD23-expressing B-cell lines. We investigated the in vivo activity of lumiliximab in a human disseminated CD23(+) B-cell lymphoma SCID mouse model and found greater antitumor activity with it than with control antibody. We also found that paralysis-free survival was greater with lumiliximab plus rituximab or fludarabine than with any of those agents alone. These results suggest that lumiliximab may be an effective treatment alone or in combination with rituximab or chemotherapy agents in CLL or other CD23-overexpressing B-cell malignancies.
AuthorsNuzhat I Pathan, Peter Chu, Kandasamy Hariharan, Carolyn Cheney, Arturo Molina, John Byrd
JournalBlood (Blood) Vol. 111 Issue 3 Pg. 1594-602 (Feb 01 2008) ISSN: 0006-4971 [Print] United States
PMID18032710 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Caspase Inhibitors
  • Mitochondrial Proteins
  • Protease Inhibitors
  • Receptors, IgE
  • bcl-2-Associated X Protein
  • lumiliximab
  • Caspases
  • Vidarabine
  • fludarabine
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology)
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Caspase Inhibitors
  • Caspases (metabolism)
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (pathology)
  • Lymphoma (metabolism, pathology)
  • Mice
  • Mitochondria (drug effects, metabolism)
  • Mitochondrial Proteins (metabolism)
  • Protease Inhibitors (pharmacology)
  • Receptors, IgE (metabolism)
  • Signal Transduction (drug effects)
  • Survival Rate
  • Tumor Cells, Cultured
  • Vidarabine (analogs & derivatives, pharmacology)
  • Xenograft Model Antitumor Assays
  • bcl-2-Associated X Protein (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: